BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Company News  |  Deals

Beckman Coulter, Transgene deal

Beckman Coulter will develop a companion diagnostic for Transgene to select patients for Transgene's cancer candidate TG4010. The diagnostic will measure levels of triple-positive activated natural killer (NK) cells. Transgene said a previous trial in non-small cell...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >